Exchange: NASDAQ Sector: Technology Industry: Software—Application
-2.23% $5.27
America/New_York / 18 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 644.06 mill |
EPS: | -0.180 |
P/E: | -29.28 |
Earnings Date: | Mar 19, 2024 |
SharesOutstanding: | 122.21 mill |
Avg Daily Volume: | 0.0698 mill |
RATING 2024-04-18 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Sell | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Sell | |
P/E: | Neutral | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | ||
Gr.Profit | n/a | n/a | n/a | n/a | ||
Ebit | n/a | n/a | ||||
Asset | n/a | n/a | n/a | |||
Debt | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -29.28 | sector: PE -1.697 |
PE RATIO: COMPANY / INDUSTRY |
---|
0x |
Company: PE -29.28 | industry: PE -81.55 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 4.54 - 6.00 ( +/- 13.93%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-07-25 | Waldencast Long-term Capital Llc | Sell | 8 545 000 | Class B ordinary shares |
2021-08-17 | Festetics Tassilo | Buy | 0 | |
2021-12-16 | Chatterley Aaron | Buy | 0 | |
2021-03-18 | Sebti Hind | Buy | 0 | |
2021-03-18 | Waldencast Long-term Capital Llc | Sell | 8 545 000 | Class B ordinary shares |
INSIDER POWER |
---|
-100.00 |
Last 6 transactions |
Buy: 0 | Sell: 17 170 000 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $5.27 (-2.23% ) |
Volume | 0.0771 mill |
Avg. Vol. | 0.0698 mill |
% of Avg. Vol | 110.50 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Waldencast Acquisition Corp. a skin care company, provides advanced skin care treatments. Its products are designed to help minimize the appearance of premature skin aging, skin damage, hyperpigmentation, acne, and sun damage primarily available through dermatologists, plastic surgeons, medical spas, and other skin care professionals. Its portfolio includes Obagi Medical that provides transformational skin care products formulated to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines, and wrinkles and to protect and enhance skin tone and texture; and Obagi Clinical that offers skin care products designed to prevent the early signs of skin aging. The company was founded in 1988 and is based in White Plains, New York.